when prescribing n Use generic equivalents for GDMT whenever possible n Work with a pharmacist, social worker, or patient navigator to identify and navigate Patient Assistance Programs n Request price matching if a drug is found at a lower cost at another pharmacy GDMT guideline-directed medical therapy. Helpful Information for Completion of Prior Authorization Forms* Patient Criteria n Include HF phenotype: HFrEF; HFpEF n Identify NYHA functional class n Include recent measurement of LVEF with source documentation if requested n Identify the treatment requested or the additional testing required, with indications supported by evidence and/or guideline statements where applicable; clinical judgment, especially for testing requests, is an appropriate rationale n Address previous therapies used and the rationale for switching to or adding the requested treatment n Address known contraindications to use, adverse effects, and steps intended to minimize the risks of drugs or procedures n Document, when appropriate, that delays or interruptions in therapy may cause harm to the patient n Work with local pharmacy resources and pharmacy professionals to jointly address prior authorization requirements; do not hesitate to ap- peal decisions that are contrary to the best patient care. Document all steps taken in the patient s health record. *Required information may vary depending on payer and state. HF heart failure; HFpEF heart failure with preserved ejection fraction; HFrEF heart failure with reduced ejection fraction, LVEF left ventricular ejection fraction; NYHA New York Heart Association. Maddox et al. J patients with HFrEF. As detailed in Table 14, the modu- lation of 12 pathophysiological targets has now been shown to improve symptoms and/or outcomes for pa- tients with HFrEF. These targets include not only those modulated by the recommended treatments in this document, but also emerging treatments. 